(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Raw oysters linked to ongoing salmonella outbreak infecting 64 across 22 states: CDC - 2Heartfelt Objections to Visit with Your Adored One
- 3South Carolina's measles outbreak reaches 434 cases
- 4Tzrifin base exhibition reveals Hamas and Hezbollah arms, showing structure behind attacks
- 5'The Golden Bachelor' Season 2 finale: How to watch tonight, start time, where to stream and more
- 41 Young Men Die in South Africa After Circumcision Initiation
- Famous Places to get-away for Americans
- Why is the Artemis 2 rocket launch different from all other rocket launches?
- Flat Earth, spirits and conspiracy theories – experience can shape even extraordinary beliefs
- Careful Nurturing: Techniques for Bringing up Tough Children
- 10 Demonstrated Tips to Dominate Video Altering on Your Cell phone in 2023
- KJ Apa stars as Jimmy Stewart in new biopic: See his transformation
- The most effective method to Succeed in Your Web based Advertising Degree: Procedures for Progress
- OPEC’s No. 2 Producer Burns Its Own Gas—Then Buys Iran’s
